Search clinical trials for: Selexipag

Total 33 results

Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield; University of Cambridge; University of Newcastle Upon-Tyne and other collaborators

Recruiting

Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (PHoenix)

Pulmonary Arterial Hypertension

United Kingdom
Hospital Costa del Sol
Hospital Universitario Virgen Macarena; Hospital San Juan de la Cruz; Hospitales... and other collaborators

Recruiting

RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists (RAMPHA)

Pulmonary Arterial Hypertension

Spain
Actelion

Recruiting

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option (PLATYPUS)

Hypertension, Pulmonary

Korea, Republic of, Taiwan, Poland, Bulgaria, Ukraine, Belgium, South Africa, Belarus, Russian Federation
Technische Universität Dresden
GWT-TUD GmbH

Recruiting

COMPERA / COMPERA-KIDS (COMPERA)

Pulmonary Arterial Hypertension (PAH) | Pulmonary Hypertension (PH)

Germany, Belgium, Italy, Switzerland
Actelion

Active, not recruiting

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Belgium, Taiwan, Israel, United States, France, China, United Kingdom, Malaysia, Belarus, Canada, Germany, Hungary, Russian Federation, Serbia, Ukraine, Poland
Janssen-Cilag S.p.A.

Completed

A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag (INSPECTIO)

Pulmonary Arterial Hypertension

Italy
Actelion

Active, not recruiting

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension (SALTO)

Hypertension, Pulmonary

United States, Belgium, Korea, Republic of, Taiwan, Canada, Israel, Russian Federation, Switzerland, France, Thailand, Poland, China, Hungary, Spain, Turkey, Belarus, Germany, Serbia, Bulgaria, Brazil, Mexico, Italy, Sweden, Ireland, Ma... and more
Actelion

Terminated

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag (SPHINX)

Sarcoidosis-associated Pulmonary Hypertension

United States, Germany, Canada, United Kingdom, Belgium, France, Netherlands, Italy, Brazil, Spain
Actelion

Completed

A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study (SOMBRERO)

Hypertension, Pulmonary

Taiwan, Korea, Republic of, Belarus, India, Romania, Ukraine
Actelion

Available

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Thromboangiitis Obliterans | Non-healing Wound
Actelion

Terminated

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging (RESTORE)

Pulmonary Arterial Hypertension

Germany, Korea, Republic of, Israel, Singapore, United States, Russian Federation, Brazil, Netherlands, Malaysia, Saudi Arabia, United Kingdom, Hong Kong, France, United Arab Emirates, Argentina
Actelion

Completed

ACT-293987 in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Poland, Ukraine, United Kingdom, China, Germany, Taiwan, France, Spain, Switzerland, Argentina, Belarus, Belgium, Colombia, Israel, India, Malaysia, Romania, Serbia, Canada, Australia, Netherlands, Denmark, Greece, Korea,... and more
Actelion

Completed

Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United Kingdom, Austria, Belgium, France, Germany, Hungary, Italy, Poland
Actelion

Terminated

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment (SELECT)

Chronic Thromboembolic Pulmonary Hypertension

United States, Taiwan, Belgium, Canada, Korea, Republic of, United Kingdom, Turkey, Poland, Austria, Portugal, Spain, Italy, Switzerland, China, Malaysia, Netherlands, Australia, Thailand, Hungary, Brazil, Bulgaria, Czechia, Germany, ... and more
Sanofi

Terminated

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Anemia

United States
Actelion

Completed

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (TRITON)

Pulmonary Arterial Hypertension

United States, Spain, Denmark, Canada, Germany, United Kingdom, Belgium, Austria, Netherlands, Australia, France, Ireland, Sweden, Italy, Switzerland
Actelion

Completed

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. (TRACE)

Pulmonary Arterial Hypertension

United States, United Kingdom, Ireland, Germany, Austria, France, Norway, Portugal, Sweden, Switzerland
University of Sao Paulo General Hospital
Janssen-Cilag Ltd.

Unknown

Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension (SELSCH)

Pulmonary Hypertension | Schistosomiasis

Brazil
Actelion

Completed

A Study of Selexipag in Healthy Male Participant

Healthy

Belgium
Actelion

Completed

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Germany
Actelion
Canadian Heart Research Centre

Completed

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (PAH QuERI Ext)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Actelion

Completed

A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects

Healthy Subjects

Belgium
Actelion

Completed

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension (TRANSIT-1)

Pulmonary Arterial Hypertension

United States
Actelion

Completed

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (GRIPHON)

Pulmonary Arterial Hypertension

United States, Canada, Colombia, Malaysia, Austria, Israel, Ukraine, Germany, Australia, China, Argentina, Mexico, Spain, Hungary, Belarus, Belgium, Chile, Czechia, Denmark, France, Greece, India, Ireland, Italy, Korea, Republic of, Nethe... and more
Cairo University

Unknown

The Effect of Lidocaine - Prilocaine Cream (EMLA) Versus Mepivacaine Infiltration on Pain Relief During And After Mediolateral Episiotomies

Episiotomy Pain

Egypt
United Therapeutics

Withdrawn

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Pulmonary Arterial Hypertension
Actelion

Completed

Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects

Healthy Subjects

France
Actelion

Completed

Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects

Healthy Subjects

France
Actelion

Completed

A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects

Healthy Subjects

Germany
Actelion

Completed

Comparison of Two Dose Strengths of Selexipag in Healthy Adults

Healthy Subjects

Germany
Actelion

Completed

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Raynaud's Phenomenon Secondary to Systemic Sclerosis

Germany, France, United Kingdom
Actelion

Completed

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

Pharmacokinetics | Tolerability | Safety | Cardiodynamics

United States
Actelion

Completed

Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg

Bioequivalence

Netherlands

Search clinical trials for: Selexipag

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations